Melissa Nardi is a Flow Cytometry Scientist within the Diagnostic Pathology Laboratory at the Peter MacCallum Cancer Centre, with a specialised interest in spectral flow cytometry. Her current work focuses on the validation and implementation of Spectral Measurable Residual Disease (MRD) assays. One of her key projects involves the validation of a 24‑colour spectral B‑Acute Lymphoblastic Leukaemia (B‑ALL) MRD assay on the Cytek Northern Lights.
She began her career as a Haematology Scientist and developed a strong interest in flow cytometry. She later worked as a Senior Technical Officer at ARAFlowCore, where she provided flow cytometry training and experimental design support for translational research staff. During this period she became particularly passionate about spectral flow cytometry and its potential to enhance clinical diagnostics and disease monitoring.
She is enthusiastic about the adoption of emerging technologies and her career goals centre on supporting clinical laboratories as they transition to utilising spectral flow cytometry in routine practice.